RANBAXY LAB - BUY

India's largest pharma company not need any explanation for the investors. After the take over of Daiichi Sankyo ,initial hiccups on integration of management is almost over .Under the new leadership,company is expected to perform well going forward.In the latest qtr ,Ranbaxy's domestic sales posted very good performance but it partially offset by the not so good sales outside.Company is expected better performance in near future due to the beginning of the supply of Nexium API and formulations.In an effort to strengthen its local sale,company recently recruited more than 1000 field staff.All these efforts under the new management is expected to help the company to capture the past glory. Investors can add Ranbaxy  in their portfolio for long term gains.Considering the volatility in the  market ,it is better to buy in small lots.CMP is Rs.570/-